Generate Biomedicines (NASDAQ:GENB) Stock Price Up 8.1% – Time to Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price rose 8.1% during mid-day trading on Monday . The stock traded as high as $14.12 and last traded at $14.2090. Approximately 77,430 shares traded hands during trading, a decline of 84% from the average daily volume of 476,821 shares. The stock had previously closed at $13.15.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Piper Sandler began coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 target price for the company. Morgan Stanley assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective for the company. Guggenheim initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating on the stock. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.20.

Generate Biomedicines Stock Down 0.8%

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.